1163 A novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, BCG033, demonstrates preclinical efficacy against triple-negative breast cancer xenografts

Abstract

BackgroundPatients with metastatic triple-negative breast cancer (TNBC) have low rates of overall survival, indicating the need to develop novel treatments. Although the TROP2-targeting ADC sacituzumab govitecan was recently granted accelerated...